AMI Asset Management Corp Sells 6,800 Shares of Labcorp Holdings Inc. $LH

Key Points

• AMI Asset Management reduced its Labcorp stake by 4%, selling 6,800 shares and retaining 163,755 shares worth approximately $50.5 million at quarter-end.
• Institutional investors own 95.94% of Labcorp, while company insiders sold 8,593 shares valued at roughly $2.7 million during the latest quarter.
• Analysts maintain a “Moderate Buy” consensus with an average price target of $337.73; Labcorp recently exceeded quarterly earnings and revenue expectations and issued fiscal 2026 EPS guidance of $18.10–$18.55.

AMI Asset Management Corp reduced its holdings in Labcorp Holdings Inc. (NYSE:LH - Free Report) by 4.0% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 163,755 shares of the medical research company's stock after selling 6,800 shares during the period. Labcorp makes up about 2.9% of AMI Asset Management Corp's investment portfolio, making the stock its 13th biggest position. AMI Asset Management Corp owned approximately 0.20% of Labcorp worth $50,455,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of LH. Allied Private Wealth LLC bought a new position in shares of Labcorp in the 2nd quarter worth $33,000. Cedar Mountain Advisors LLC grew its stake in shares of Labcorp by 786.7% during the first quarter. Cedar Mountain Advisors LLC now owns 133 shares of the medical research company's stock worth $35,000 after purchasing an additional 118 shares during the period. SHP Wealth Management bought a new stake in Labcorp in the fourth quarter valued at about $40,000. Jones Financial Companies Lllp bought a new stake in Labcorp in the second quarter valued at about $58,000. Finally, Steph & Co. bought a new stake in Labcorp in the first quarter valued at about $64,000. 95.94% of the stock is owned by institutional investors.

Insider Transactions at Labcorp

In related news, EVP Amy Summy sold 924 shares of the firm's stock in a transaction on Tuesday, August 4th. The shares were sold at an average price of $306.74, for a total transaction of $283,427.76. Following the sale, the executive vice president directly owned 6,956 shares in the company, valued at $2,133,683.44. This trade represents a 11.73% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Adam Schechter sold 4,669 shares of the business's stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $320.37, for a total transaction of $1,495,807.53. Following the completion of the sale, the chief executive officer directly owned 102,565 shares in the company, valued at $32,858,749.05. This represents a 4.35% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 8,593 shares of company stock valued at $2,733,295 over the last quarter. Corporate insiders own 0.84% of the company's stock.

Analyst Ratings Changes

A number of equities analysts have issued reports on the company. Barclays raised their target price on Labcorp from $320.00 to $330.00 and gave the stock an "equal weight" rating in a report on Friday, September 11th. UBS Group boosted their target price on Labcorp from $361.00 to $380.00 and gave the stock a "buy" rating in a research report on Friday, September 11th. Robert W. Baird set a $352.00 price target on Labcorp in a research note on Friday, July 31st. Morgan Stanley increased their price target on shares of Labcorp from $308.00 to $338.00 and gave the company an "overweight" rating in a research report on Friday, July 31st. Finally, Truist Financial increased their price target on shares of Labcorp from $350.00 to $365.00 and gave the company a "buy" rating in a research report on Monday, September 21st. Eight equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $337.73.

Labcorp Stock Performance

Shares of Labcorp stock opened at $322.90 on Wednesday. The stock's fifty day simple moving average is $320.55 and its 200 day simple moving average is $289.98. The company has a current ratio of 1.80, a quick ratio of 1.53 and a debt-to-equity ratio of 0.69. The company has a market capitalization of $26.19 billion, a PE ratio of 18.23, a PEG ratio of 1.82 and a beta of 0.87. Labcorp Holdings Inc. has a 12 month low of $244.52 and a 12 month high of $341.80.

Labcorp (NYSE:LH - Get Free Report) last posted its earnings results on Thursday, July 30th. The medical research company reported $4.99 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $4.78 by $0.21. Labcorp had a return on equity of 16.74% and a net margin of 6.99%. The firm had revenue of $3.73 billion during the quarter, compared to analysts' expectations of $3.71 billion. During the same period in the previous year, the firm earned $4.35 earnings per share. The company's revenue was up 5.8% on a year-over-year basis. Labcorp has set its FY 2026 guidance at 18.100-18.550 EPS. On average, research analysts predict that Labcorp Holdings Inc. will post 18.32 EPS for the current year.

About Labcorp

Labcorp NYSE: LH, formally Laboratory Corporation of America Holdings, is a global life sciences and healthcare company headquartered in Burlington, North Carolina. The company provides laboratory testing and diagnostic services to physicians, hospitals, health systems, employers, insurers and consumers.

Through its diagnostics operations, Labcorp offers routine and specialty testing, oncology diagnostics, women's health testing, genetic testing, pathology services and other laboratory services.

Want to see what other hedge funds are holding LH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Labcorp Holdings Inc. (NYSE:LH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.